Core Viewpoint - The FDA highlighted serious safety concerns related to semaglutide, marketed by Novo as Ozempic and Wegovy, including two deaths and a suicide linked to its use [1] Group 1 - The FDA's emphasis on adverse events raises questions about the safety profile of semaglutide [1] - Novo's marketing of semaglutide as a treatment option may face increased scrutiny following these incidents [1] - The reported cases could impact public perception and regulatory stance towards semaglutide products [1]